Pure Biologics S.A. (WSE:PUR)

Market Cap	26.16M
Revenue (ttm)	n/a
Net Income (ttm)	-17.53M
Shares Out	4.08M
EPS (ttm)	-4.52
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	24,560
Average Volume	42,992
Open	6.44
Previous Close	6.47
Day's Range	6.25 - 6.57
52-Week Range	2.22 - 21.85
Beta	1.04
RSI	48.75
Earnings Date	Nov 14, 2025

About Pure Biologics

Pure Biologics S.A., a biopharmaceutical company, engages in the research and development of biological drugs and non-systematic therapies in the field of immuno-oncology, autoimmunology, and rare neurological diseases. It is involved in the production, purification, analysis, and characterization of antibodies and aptamers; and design, development, and validation of assays, as well as conducts research on technology platforms for selecting active molecules. The company offers PureApta, a modular platform for in vitro selection of modified apta...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2010
• Employees: 7
• Stock Exchange: Warsaw Stock Exchange
• Ticker Symbol: PUR